 |
 Video: What is a Stock Split?
|
|
|
| Viridian Therapeutics is a biopharmaceutical company. Co. has built relevant capabilities in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (TED) and other undisclosed target indications in rare and autoimmune diseases. Co. is developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that are being developed for intravenous or subcutaneous administration to treat patients who suffer from TED. Co.'s primary program, VRDN-001, is a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor intravenously administered for the treatment for TED. According to our Viridian Therapeutics stock split history records, Viridian Therapeutics has had 0 splits. | |
|
Viridian Therapeutics (VRDN) has 0 splits in our Viridian Therapeutics stock split history database.
Looking at the Viridian Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Viridian Therapeutics shares, starting with a $10,000 purchase of VRDN, presented on a split-history-adjusted basis factoring in the complete Viridian Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/19/2014 |
|
| End date: |
05/01/2024 |
|
| Start price/share: |
$8.45 |
|
| End price/share: |
$13.81 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
63.43% |
|
| Average Annual Total Return: |
5.10% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$16,341.98 |
|
| Years: |
9.87 |
|
|
|
|
|
